{"id":"NCT03713632","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)","officialTitle":"A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-25","primaryCompletion":"2021-09-23","completion":"2022-07-19","firstPosted":"2018-10-22","resultsPosted":"2023-08-02","lastUpdate":"2024-10-09"},"enrollment":545,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hidradenitis Suppurativa"],"interventions":[{"type":"DRUG","name":"Secukinumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab 1","type":"ACTIVE_COMPARATOR"},{"label":"Secukinumab 2","type":"ACTIVE_COMPARATOR"},{"label":"Placebo 1","type":"PLACEBO_COMPARATOR"},{"label":"Placebo 2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.","primaryOutcome":{"measure":"Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)","timeFrame":"16 weeks","effectByArm":[{"arm":"AIN457 Q2W","deltaMin":42.3,"sd":null},{"arm":"AIN457 Q4W","deltaMin":46.1,"sd":null},{"arm":"Placebo","deltaMin":31.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0149"},{"comp":"OG001 vs OG002","p":"0.0022"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":108,"countries":["United States","Argentina","Belgium","Bulgaria","Canada","Colombia","Croatia","Czechia","Denmark","France","Germany","Greece","Guatemala","Hungary","India","Israel","Italy","Lebanon","Lithuania","Malaysia","Netherlands","Philippines","Poland","Russia","Singapore","Slovakia","South Africa","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom","Vietnam"]},"refs":{"pmids":["40839197","40372667","39425517","39101698","36746171"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1840"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":180},"commonTop":["Headache","Hidradenitis","Nasopharyngitis","Diarrhoea","Upper respiratory tract infection"]}}